Introduction: Higher incidence and growth of intracerebral hemorrhage (ICH) has been reported with primary hypocholesterolemia. Statins have been associated with improved outcome in ICH patients, although they lower low density lipoprotein (LDL) cholesterol. Our study explores whether lower admission LDL secondary to statin use is associated with admission ICH hematoma volumes (HV) or hematoma growth (HG). METHODS: Data from the Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study, a multicenter case-control study designed to examine ethnic variations in the risk, presentation, and outcomes of ICH, were analyzed to explore the association of statin use and LDL with HV and HG. The Kruskal-Wallis test was used to examine differences in initial volume between groups, and the Wilcoxon Signed-Rank test was used to examine differences in HV between patients’ first two CT scans. RESULTS: Among cases enrolled prior to January 2013, 544 (mean±SD age=60.9±14.1, 60.3% male) had both admission LDL data and CT scan within 24 hours of onset. Four groups were defined: 1) statin use and LDL<70, n=42 (7%); 2) statin use and LDL≥70, n=79 (14%); 3) no statin use and LDL<70, n=58 (10%); and 4) no statin use and LDL≥70, n=365 (67%). There was no difference in admission HV among groups (p=.69). Follow up (f/u) imaging was available for 350 (64.3%) cases: n for the 4 groups was 26 (7%), 47 (13%), 35 (10%), and 242 (69%). Compared with baseline CT, the non-statin users had significantly higher f/u HV (p<.0001), whereas f/u HV was unchanged for statin users (p=.529). Group analysis showed decreased HV in group 1 and increased HV in group 4 (Figure 1). CONCLUSION: There was no association between LDL<70 with or without statin use and admission HV. When compared with non-statin users, statin users, especially with LDL<70, had reduced HG on f/u scans. Further studies are needed to explore these findings.